BALAXIPharmaceuticals
Balaxi Pharmaceuticals Ltd — Profit & Loss Statement
₹15.67
-9.20%
Balaxi Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | -11.49 Cr | 0.00 | 0.00 | — |
| Tax Rate For Calcs | 0.13 | 0.30 | 0.19 | 0.13 | — |
| Normalized EBITDA | 33.50 Cr | 44.08 Cr | 59.17 Cr | 55.18 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 25.07 Cr | -2.39 Cr | 45.96 Cr | 47.66 Cr | — |
| Reconciled Depreciation | 1.89 Cr | 2.10 Cr | 1.75 Cr | 0.51 Cr | — |
| Reconciled Cost Of Revenue | 165.70 Cr | 128.68 Cr | 202.42 Cr | 195.60 Cr | — |
| EBITDA | 33.50 Cr | 5.79 Cr | 59.17 Cr | 55.18 Cr | — |
| EBIT | 31.60 Cr | 3.69 Cr | 57.42 Cr | 54.66 Cr | — |
| Net Interest Income | -2.93 Cr | -1.68 Cr | -1.38 Cr | -0.76 Cr | — |
| Interest Expense | 2.93 Cr | 1.68 Cr | 0.50 Cr | 0.14 Cr | — |
| Normalized Income | 25.07 Cr | 24.42 Cr | 45.96 Cr | 47.66 Cr | — |
| Net Income From Continuing And Discontinued Operation | 25.07 Cr | -2.39 Cr | 45.96 Cr | 47.66 Cr | — |
| Total Expenses | 257.24 Cr | 196.66 Cr | 280.77 Cr | 229.08 Cr | — |
| Diluted NI Availto Com Stockholders | 25.07 Cr | -2.39 Cr | 45.96 Cr | 47.66 Cr | — |
| Net Income Common Stockholders | 25.07 Cr | -2.39 Cr | 45.96 Cr | 47.66 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 25.07 Cr | -2.39 Cr | 45.96 Cr | 47.66 Cr | — |
| Net Income Including Noncontrolling Interests | 25.07 Cr | -2.39 Cr | 45.96 Cr | 47.66 Cr | — |
| Net Income Continuous Operations | 25.07 Cr | -2.39 Cr | 45.96 Cr | 47.66 Cr | — |
| Tax Provision | 3.60 Cr | 4.40 Cr | 10.96 Cr | 6.86 Cr | — |
| Pretax Income | 28.67 Cr | 2.02 Cr | 56.92 Cr | 54.52 Cr | — |
| Other Non Operating Income Expenses | -3.72 Cr | -2.65 Cr | 0.77 Cr | 0.03 Cr | — |
| Net Non Operating Interest Income Expense | -2.93 Cr | -1.68 Cr | -1.38 Cr | -0.76 Cr | — |
| Interest Expense Non Operating | 2.93 Cr | 1.68 Cr | 0.50 Cr | 0.14 Cr | — |
| Operating Income | 35.32 Cr | 44.63 Cr | 55.66 Cr | 50.31 Cr | — |
| Operating Expense | 91.54 Cr | 67.98 Cr | 78.35 Cr | 33.48 Cr | — |
| Depreciation And Amortization In Income Statement | 1.89 Cr | 2.10 Cr | 1.75 Cr | 0.51 Cr | — |
| Depreciation Income Statement | 1.89 Cr | 2.10 Cr | 1.75 Cr | 0.51 Cr | — |
| Selling General And Administration | 54.91 Cr | 37.85 Cr | 32.10 Cr | 14.16 Cr | — |
| General And Administrative Expense | 54.91 Cr | 37.85 Cr | 31.26 Cr | 13.14 Cr | — |
| Gross Profit | 126.86 Cr | 112.61 Cr | 134.02 Cr | 83.79 Cr | — |
| Cost Of Revenue | 165.70 Cr | 128.68 Cr | 202.42 Cr | 195.60 Cr | — |
| Total Revenue | 292.56 Cr | 241.29 Cr | 336.43 Cr | 279.39 Cr | — |
| Operating Revenue | 292.56 Cr | 241.29 Cr | 336.43 Cr | 279.39 Cr | — |
| Total Unusual Items | — | -38.29 Cr | 0.00 | 0.00 | -0.04 Cr |
| Total Unusual Items Excluding Goodwill | — | -38.29 Cr | 0.00 | 0.00 | -0.04 Cr |
| Rent Expense Supplemental | — | 7.89 Cr | 9.91 Cr | 3.49 Cr | 1.21 Cr |
| Diluted Average Shares | — | 5.19 Cr | 5.06 Cr | 5.00 Cr | 5.00 Cr |
| Basic Average Shares | — | 5.19 Cr | 5.02 Cr | 5.00 Cr | 5.00 Cr |
| Diluted EPS | — | -0.46 | 9.08 | 9.53 | 7.63 |
| Basic EPS | — | -0.46 | 9.16 | 9.53 | 7.63 |
| Special Income Charges | — | -38.29 Cr | 0.00 | 0.00 | -0.04 Cr |
| Other Special Charges | — | 38.29 Cr | — | — | — |
| Total Other Finance Cost | — | 1.09 Cr | 0.88 Cr | 0.62 Cr | 0.26 Cr |
| Other Operating Expenses | — | 0.21 Cr | 4.75 Cr | 2.37 Cr | 0.65 Cr |
| Selling And Marketing Expense | — | 0.66 Cr | 0.84 Cr | 1.02 Cr | 0.10 Cr |
| Rent And Landing Fees | — | 7.89 Cr | 9.91 Cr | 3.49 Cr | 1.21 Cr |
| Net Income Discontinuous Operations | — | — | 0.00 | 0.00 | 0.00 |
| Write Off | — | — | — | 0.00 | 0.04 Cr |
| Interest Income | — | — | — | — | 18000.00 |
| Interest Income Non Operating | — | — | — | — | 18000.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Balaxi Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.